InvestorsHub Logo
Followers 283
Posts 1162
Boards Moderated 0
Alias Born 10/04/2020

Re: None

Thursday, 08/19/2021 4:26:47 PM

Thursday, August 19, 2021 4:26:47 PM

Post# of 118421
Closed UP Nearly 30%

Now THAT's a Game Changer!

Looks like everyone got wind of Pink Limited TODAY and know that Pink Current is STRAIGHT AHEAD!

We could go PINK CURRENT ANY DAY EVEN LATER TODAY OR TOMORROW!!

....then WORLD WIDE BUYING will set it rapidly and cause the PPS to Sky Rocket!

My Prediction is RGBP will easily surpass ENZC's run in February and it wouldn't surprise me at all if our first major run is to $1.25 to $1.50, keeping in mind that ENZC's run hit nearly $1.00 six months ago and had A LOT LESS going for it then, compared to what RGBP has TODAY!!! In fact no comparison!

Here's a recap of why RGBP should surpass ENZC's run:

ENZC had:
#1 (1) Patent only
#2 No FDA approval
#3 No licensing arrangements
#4 No partnerships
#5 No catalysts
#6 No PR releases
#7 No prospect of revenue (due to #2 & #3)
#8 No suggestion of Buy Out by CEO

RGBP has:

#1 20+ Patents worth $BILLIONS

#2 Licensing of (1) Patent with (2) INDs (New Drug Applications) for treating pancreatic & colon cancer by mRNA Vaccine-"The Future of Medicine"

#3 Recent FDA Patent Approval for Clinical Trials.

#4 Partnership: Received $1.1 Million up front payment from Oncology Pharma for Patent Licensing and is NOW positioned to receive Quarterly Revenues for 15 YEARS! (Totally unheard of for ANY OTC Stock)

#5 Going Pink Current IMMINENT ANY DAY = Instant buying capacity World Wide!

#6 CEO suggests Buy Out by filing an 8K on 4/27/21 to protect against a Hostile Take Over that specifically states "parties interested to ACQUIRE must negotiate directly."

I'm fully expecting RGBP to run North of $1.00 short term Post Pink Current, and $2+ by end of year if not higher!

Then there's the very real specter of a Big Pharma Buy Out or Merger Acquisition that most everyone here already knows about based on Koos filing that 8K on 4/27/21 that protects against a Hostile Take Over!

Based on what RGBP has today, I view it as a "Hybrid" NASDAQ stock based on its extensive portfolio of Disruptive Biotechnology Patents some of which are mRNA based which very clearly is the Future of Medicine, recent FDA Patent approval, AND being positioned for Quarterly Revenues. It simply doesn't get any better than this on the OTC.

Look for my next Post on the Top 5 possible Buy Out-Merger Acquisition Big Pharma players that I believe may be the suitors to acquire RGBP in the days ahead!

Be well and prosper...